Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency testing is not
routinely performed before primaquine treatment in most Plasmodium vivax endemic areas …

Background G6PD deficiency is common in malaria endemic regions and is estimated to
affect more than 400 million people worldwide. Treatment of malaria patients with the anti …

Background This study aimed to evaluate the prevalence and alteration of hematological
parameters in malaria patients with a glucose-6-phosphate dehydrogenase (G6PD) …

Background Pakistan has an estimated annual burden of 1.5 million malaria cases. The
current situation calls for an effective malaria control and eradication programme in this …

Background Primaquine is the only drug consistently effective against mature gametocytes
of Plasmodium falciparum. The transmission blocking dose of primaquine previously …

Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-
linked hereditary enzymatic abnormality that affects more than 400 million people …

Background The use of primaquine for mass drug administration (MDA) is being considered
as a key strategy for malaria elimination. In addition to being the only drug active against the …

Background Plasmodium vivax occurs as a latent infection of liver and a patent infection of
red blood cells. Radical cure requires both blood schizontocidal and hypnozoitocidal …

Abstract Glucose-6-phosphate dehyrdgoenase (G6PD) deficiency is a common X-linked
genetic trait, with an associated enzyme phenotype, whereby males are either G6PD …

Background Building on the declining trend of malaria in Ethiopia, the Federal Ministry of
Health aims to eliminate malaria by 2030. As Plasmodium falciparum and Plasmodium vivax …